Mucosal immune response in BNT162b2 COVID-19 vaccine recipients

Autor: Lorenzo Azzi, Daniela Dalla Gasperina, Giovanni Veronesi, Mariam Shallak, Giuseppe Ietto, Domenico Iovino, Andreina Baj, Francesco Gianfagna, Vittorio Maurino, Daniele Focosi, Fabrizio Maggi, Marco Mario Ferrario, Francesco Dentali, Giulio Carcano, Angelo Tagliabue, Lorenzo Stefano Maffioli, Roberto Sergio Accolla, Greta Forlani

Publikováno v: EBioMedicine, Vol 75, Iss, Pp 103788-(2022)
EBioMedicine

Summary: Background: Although the BNT162b2 COVID-19 vaccine is known to induce IgG neutralizing antibodies in serum protecting against COVID-19, it has not been studied in detail whether it could generate specific immunity at mucosal sites, which rep

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cb4adce58d3fba0b1536acd3fc892eb
http://hdl.handle.net/11383/2130084

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.

Autor: Einstein MH; a Montefiore Medical Center and Albert Einstein College of Medicine; Obstetrics & Gynecology and Women's Health ; Bronx , NY USA., Takacs P, Chatterjee A, Sperling RS, Chakhtoura N, Blatter MM, Lalezari J, David MP, Lin L, Struyf F, Dubin G

Publikováno v: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2014; Vol. 10 (12), pp. 3435-45.